托莫西汀应用于小儿注意缺陷多动障碍合并焦虑患者的效果观察
ffect of atomoxetine on children with attention deficit hyperactivity disorder and anxiety
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2019, 46(6) |
| 作者 |
|
| 作者单位 |
南阳市中心医院 ;
|
| 摘要 |
探讨小儿注意缺陷多动障碍（ADHD）合并焦虑患者应用托莫西汀治疗的临床效果。方法 随机数字表法将97例注意缺陷多动障碍合并焦虑患儿分为2组，常规组48例口服哌甲酯进行治疗，观察组49例予托莫西汀口服治疗，对比两组2月末焦虑及ADHD症状评分、相关神经因子水平和安全性。结果 观察组1月末患儿ADHD症状评定分量表及总量表评分、SCARED学校恐怖症、分离性焦虑、广泛性焦虑、躯体惊恐症及社交恐怖症各项评分及不良反应发生率均低于常规组，NE、DA及皮质醇水平均高于常规组，差异有统计学意义（P＜0.05）。结论 托莫西汀可改善ADHD合并焦虑患儿NE、DA水平，缓解其ADHD及焦虑相关症状，安全且有效。
|
| Abstract |
Objective To investigate the clinical effect of treatment with tomoxetine in children with attention deficit hyperactivity disorder (ADHD) and anxiety. Methods A total of 97 children with attention deficit hyperactivity disorder and anxiety were divided into 2 groups by random number table method. 48 patients in the conventional group were treated with oral methylphenidate. 49 patients in the observation group were treated with oral tomoxetine. Anxiety and ADHD symptom scores, associated neurotrophic levels and safety. Results In the observation group, the scores of the ADHD symptoms and the scores of the total scores, the SCARED school phobia, the separation anxiety, the generalized anxiety, the somatic panic disorder and the social phobia were lower than the conventional ones. The levels of NE, DA and cortisol in the group were higher than those in the conventional group, and the difference was statistically significant (P<0.05). Conclusion Tomoxetine can improve the levels of NE and DA in children with ADHD and anxiety, and relieve the symptoms of ADHD and anxiety, which is safe and effective.
|
| 关键词 |
托莫西汀；哌甲酯；小儿注意缺陷多动障碍；焦虑
|
| KeyWord |
tomoxetine; methylphenidate; children with attention deficit hyperactivity disorder; anxiety
|
| 基金项目 |
|
| 页码 |
1039-1041 |
陈振辉*.
托莫西汀应用于小儿注意缺陷多动障碍合并焦虑患者的效果观察 [J].
国际精神病学杂志.
2019; 46; (6).
1039 - 1041.